Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab for chronic rhinosinusitis with recurrent nasal polyps
IRCT20220218054057N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of omalizumab in chronic rhinosinusitis with nasal polyps (CRSwNP) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Change in SNOT-22 score, Total Nasal Score improvement and 3 more. Started Jan 2023; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on IRCT20220218054057N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220218054057N1.